MGD-024

N/A

Report date: 2026/03/19 17:01:30

Base Information

Drug NameMGD-024
Drug Alias NameMGD-024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-CD123
TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesHodgkin Disease +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncMacrogenics Inc
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesHodgkin Disease +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A